Published on 04/12/2025

Bias & Fairness: Definitions That Matter in GxP

As the pharmaceutical industry increasingly adopts artificial intelligence and machine learning (AI/ML) technologies, understanding bias and fairness in these models is critical. This tutorial is designed to help pharmaceutical professionals navigate the complexities of AI/ML model validation while ensuring compliance with Good Practice (GxP) regulations set forth by regulatory bodies such as the FDA, EMA, and MHRA. The focus will be on intended use, data readiness, bias and fairness testing, model verification and validation, and explainability (XAI).

Step 1: Understand the Regulatory Landscape

Before engaging in any AI/ML projects in the pharmaceutical sector, it is imperative to grasp the relevant regulations and guidelines that govern model validation. The following standards are particularly relevant:

• 21 CFR Part 11: This regulation addresses electronic records and electronic signatures in the pharmaceutical industry.
• Annex 11: Pertains to computerized systems in European GMP, offering guidance on the validation of computer systems.
• GAMP 5: A framework that categorizes software and hardware for validation based on complexity and risk.

Understanding these regulations will set the foundation for intended use risk assessments and address the compliance requirements for data readiness curation.

Step 2: Define Intended Use and Identify Stakeholders

Clearly defining the intended use of your AI/ML model is crucial for guiding validation efforts and addressing compliance requirements. This definition should encompass:

• The specific applications of the model within your organization.
• The target population for the model.
• The types of data inputs the model will require.

Furthermore, it is essential to involve a cross-functional team of stakeholders including data scientists, quality assurance personnel, regulatory affairs experts, and clinical operations staff. This collaboration will help ensure comprehensive coverage of all critical areas pertinent to AI governance and security.

Step 3: Ensure Data Readiness

Data readiness curation involves the preparation and management of data necessary for training and validating AI/ML models. Proper data handling ensures that the models can perform accurately and consistently. The following steps are essential:

• Data Collection: Accumulate high-quality, representative data that reflects the intended use of the model. The data should adhere to standards set by relevant regulatory bodies.
• Data Cleansing: Conduct rigorous data cleansing to eliminate noise and outliers which can lead to bias in model outcomes.
• Data Annotation: Properly label the data to facilitate supervised learning, ensuring that the model receives clear and relevant inputs.

Data readiness is a crucial part of mitigating intended use risks and ensures that subsequent bias and fairness testing can be reliably conducted.

Step 4: Conduct Bias and Fairness Testing

Once data readiness is established, it is vital to conduct bias and fairness testing to evaluate how these factors may affect model outcomes. This step involves various techniques to measure bias and ensure fairness across different demographic groups. The following methods can be employed:

• Disparate Impact Analysis: Assess the impact of the model across subgroups to detect any statistical disparities that could indicate bias.
• Fairness Metrics: Utilize specific metrics such as Equal Opportunity, Demographic Parity, and Predictive Parity to quantify fairness and bias levels.
• Adversarial Debiasing: Implement techniques that adjust the model to improve fairness without significantly affecting performance.

Documenting these tests is crucial, as regulatory bodies place emphasis on providing evidence of due diligence in mitigating bias when validating models.

Step 5: Model Verification and Validation

Model verification and validation (V&V) are critical processes that ensure that the AI/ML model meets its intended specifications. Verification confirms that the model correctly implements the intended algorithms, while validation establishes that the model performs as expected in real-world scenarios. The steps involved include:

• Verification: Check that the algorithms are implemented correctly by conducting unit tests and integration tests.
• Validation: Use various methodologies, such as k-fold cross-validation, to assess the model’s performance accuracy and reliability.
• Performance Metrics: Assess key performance indicators (KPIs) aligned with the intended use to determine efficacy.

Documentation throughout this stage is vital for constructing audit trails that regulatory authorities require. Clear and comprehensive records will demonstrate compliance and support data integrity.

Step 6: Ensure Explainability and Interpretability

Explainability (XAI) is becoming increasingly important in AI/ML applications within the pharmaceutical industry. Stakeholders must understand how and why models make decisions, especially in regulated domains. Implementing explainability techniques includes:

• Model-Agnostic Techniques: Leverage approaches like LIME (Local Interpretable Model-agnostic Explanations) and SHAP (SHapley Additive exPlanations) to provide insights into model predictions.
• Feature Importance: Identify which features drive decision-making in the model, enhancing trust among stakeholders and facilitating informed decisions.
• Documentation: Maintain records of how explainability tools have been applied to provide insights into the decision-making processes of AI systems.

Establishing model explainability can help to significantly reduce perceived risks regarding AI governance and enable better outcomes for the intended use.

Step 7: Implement Drift Monitoring and Re-validation

AI/ML models are susceptible to performance deterioration over time due to changing data distributions — a phenomenon known as drift. Therefore, organizations must establish robust mechanisms for drift monitoring & re-validation. This includes:

• Continuous Monitoring: Set up systems to monitor the model’s performance in real-time against performance benchmarks.
• Thresholds: Define acceptable performance thresholds to trigger alerts and potential interventions when drift is detected.
• Re-validation Efforts: Establish protocols for re-validating models when drift is detected, including re-assessing the data and testing again for bias and fairness.

Continuous engagement in drift monitoring ensures the longevity and reliability of AI/ML applications in a pharmaceutical context, aligning with best practices as emphasized by regulatory guidance.

Step 8: Document Everything and Prepare for Audits

Documentation is a linchpin of compliance in the realms of AI/ML model validation. The following best practices should be adhered to:

• Maintain Comprehensive Records: Ensure that all activities regarding data handling, model training, bias testing, validation, and explainability are thoroughly documented.
• Audit Trails: Develop systems that generate audit trails for all changes made to models, including data updates and algorithm adjustments.
• Internal Reviews: Schedule regular audits to verify compliance with both internal policies and external regulatory expectations.

Effective documentation will significantly ease the challenging audit processes often encountered in regulated environments and will support transparency and comprehension of AI applications.

Conclusion: Ensuring Robust AI/ML Models in Pharmaceuticals

Bias and fairness testing, along with comprehensive model verification and validation, play critical roles in the successful adoption of AI/ML technologies in the pharmaceutical sector. By following these steps — from understanding the regulatory landscape to ensuring extensive documentation and audit trails — organizations can confidently navigate the complexities of AI/ML model validation. The thorough execution of these practices will support compliance with regulations from the ICH, PIC/S, and others, ultimately leading to improved healthcare solutions through trustworthy and explainable AI systems.